Loading
The development of the 80-gene BluePrint profile, which sorts breast cancers into three biological types that differed in response to chemotherapy before surgery.
The 80-gene profile classified tumours as luminal-type, HER2-type or basal-type. In the neoadjuvant cohort, 56 per cent of patients in the basal-type group and 50 per cent in the HER2-type group had a pathological complete response.
Gene activity can refine the subtype that standard receptor staining gives.
Shares Biomarker, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/